Retrospective study of 130 patients with organconfined prostate cancer trated with brachitherapy;Estudio retrospectivo de 130 pacientes con cáncer prostático organoconfinado tratados con braquiterapia prostática

Actas Urologicas Espanolas

Volumn 29, Issue 1, 2005, Pages 47-54

  Aguilo Lucia F ^a   Suarez Novo J F ^a   Correa Generoso, R ^a   Boladeras Inglada, A Ma ^a   Polo Rubio, A ^a   Pera Fabregas J ^a   Condom Mundo, E ^a   Cinos Cope, C ^a   Guedea Edo, F ^a   Navarro Perez V ^a   Serrallach Mila, N ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Brachitherapy; Cancer; Prostate

Indexed keywords

RADIOACTIVE IODINE;

ARTICLE; BRACHYTHERAPY; CANCER STAGING; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 17844399557     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(05)73197-1     Document Type: Article

References (27)

1. Blasko J, Radge H. Transperineal ultrasound guided implantation of the prostate: morbidity and complications. Scand J Urol Nephol Suppl 1991;137:113-118.
2. Radge H, Korb LJ, Elgamal AA, Grado GL, Nadir BS. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000;89:135-141.
3. Radge H, Korb L. Brachytherapy for clinically localized prostate cancer. Semin Surg Oncol 2000;18:45-51.
4. Oliva G. Braquiterapia en cáncer de próstata. Centro de publicaciones. Ministerio de Sanidad y Consumo. Madrid, noviembre 2000.
5. Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, editores. Cancer Incidence in Five Continents. Volume VII. Lyon: International Agency for Research on Cancer 1997.
6. Berenguer A.: "Sgreening" del cancer de próstata: un problema no resuelto. Actas Urol Esp 1996;20:768-771.
7. Partin AW, Kattan MW, Subong En et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997:277.
8. Nag S, Bice W, Dewyngaert K, Prestidge B, Stock R, Yu Y . The American Brachytherapy Society recommendations for Permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiation Oncology Biol Phys, 2000;46(1): 221-230.
9. 125 prostate implantation for patient with localized prostate cancer. Int J Radiation Oncology Biol Phys 2000;47(5):1261-1266.
10. Ash D, Flynn A, Battermann J, Reijke T, Lavagnini P, Blank L. ESTRO/EAU/EORTC recommendation on permanent seed implantation for localized prostate cancer. Int J Radiation Oncology Biol Phys 2000;57:315-321.
11. Nag S, Beyer D; Friedland J, Grimm P, Nath R. American Brachytherapy society (ABS) recomendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiation Oncology Biol Phys 1999; 44(4):789-799.
12. Yu Y, Anderson LL, Li Z, Mallenberg DE, Nath R, Schell MC, Waterman FM, Wu A, Blasko JC. Permanent prostate seed implant brachytherapy: Report of the American Association of Physicist in Medicine Task Group n° 64. Med Phys 1999; october;26(10).
13. Aguiló F, Suarez JF, Guedea F, Pera J, Cinos C, Oliva G, Serrallach N. Indicaciones y Tècnica de la Braquiterapia prostática. Actas Urol Esp 2002;26:24-26.
14. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recomendations of the AAPM. Radiation Therapy Committe Task Group n° 43 Med Phys 1995 february:22 (2).
15. Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W. Brachytherapy for Carcinoma of the prostate: Technique, patient selection and clinical outcome. Seminars in Radiation Oncology January 2002;12(1):81-94.
16. Kollmeier MA, Stock Rg, Stone N. Biochemical outcomes after prostate brachytherapy with five minimal follow up: importance of patient selection and implant quality. Int J Radiation Oncology Biol Phys 2003;57(3):645-53,.
17. 125 brachytherapy. Int J Radiation Oncology Biol Phys 2001;51(1):31-40.
18. Radge H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, Landin K, Cavanagh W. Intersticial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer August 1997;87(3):442-453.
19. Radge H, Elgamal A, Snow PB, Brandt J, Bartolucci A, Nadir BS, Korb LJ. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45 Gray external beam irradiation in the treatment ot patient with clinically localized, low to high Gleason grade prostate carcinoma. Cer September 1998;83(5):989-1001.
20. Stock R, Stone N, and Cesaretti J. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiation Oncology Biol Phys 2003;56(2):448-453.
21. Potters L, Torre T, Ashley R, Leible S. Examining the role of neoadyuvant androgen deprivation in patient undergoing prostate brachytherapy. Journal of Clinical Oncology March 2000;18(6):1187-1192.
22. Merrick G, Butler W, Galbreath R, Lief J, PH.D. Five-year biochemical outcome following permanent Interstitial brachytherapy for clinical t1-t3 Prostate cancer. Int J Radiation Oncology Biol Phys 2001;51(1):41-48.
23. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate-to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiation Oncology Biol Phys 2002;52(2):444-452.
24. Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovic E. Does Hormonal manipulation in conjuntion with permanet intersticial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high risk prostate cancer? BJU Int Jan 2003;91(1):23-29.
25. 125 versus Pd103 for low-risk prostate cancer: preliminary psa outcomes from a prospective randomized multicenter trial. Int. J Radiation Oncology Biol Phys 2003; 57(5):1297-1303.
26. Yoshioka Y, Nose T, Yoshida K, Oh R, Yamada Y, Tanaka E, Yamazaki H, Inoue T, Inoue T. High-dose-rate brachytherapy as monotherapy for localized prostate cancen a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiation Oncology Biol Phys 2003;56(1):213-220.
27. Grills I, Martinez A, Hollander M, Huang R, Goldman K, Chen P, Gustafson G. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. Journal of Urology 2004;171:1098-1104.